1. Home
  2. EDTK vs AIM Comparison

EDTK vs AIM Comparison

Compare EDTK & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDTK
  • AIM
  • Stock Information
  • Founded
  • EDTK 2013
  • AIM 1966
  • Country
  • EDTK China
  • AIM United States
  • Employees
  • EDTK N/A
  • AIM N/A
  • Industry
  • EDTK Other Consumer Services
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • EDTK Real Estate
  • AIM Health Care
  • Exchange
  • EDTK Nasdaq
  • AIM Nasdaq
  • Market Cap
  • EDTK 17.3M
  • AIM 9.8M
  • IPO Year
  • EDTK 2020
  • AIM N/A
  • Fundamental
  • Price
  • EDTK $1.00
  • AIM $0.12
  • Analyst Decision
  • EDTK
  • AIM Strong Buy
  • Analyst Count
  • EDTK 0
  • AIM 2
  • Target Price
  • EDTK N/A
  • AIM $2.75
  • AVG Volume (30 Days)
  • EDTK 13.3K
  • AIM 1.1M
  • Earning Date
  • EDTK 03-21-2025
  • AIM 04-01-2025
  • Dividend Yield
  • EDTK N/A
  • AIM N/A
  • EPS Growth
  • EDTK N/A
  • AIM N/A
  • EPS
  • EDTK N/A
  • AIM N/A
  • Revenue
  • EDTK $624,365.00
  • AIM $190,000.00
  • Revenue This Year
  • EDTK N/A
  • AIM N/A
  • Revenue Next Year
  • EDTK N/A
  • AIM $1,693.10
  • P/E Ratio
  • EDTK N/A
  • AIM N/A
  • Revenue Growth
  • EDTK N/A
  • AIM N/A
  • 52 Week Low
  • EDTK $0.84
  • AIM $0.11
  • 52 Week High
  • EDTK $1.27
  • AIM $0.62
  • Technical
  • Relative Strength Index (RSI)
  • EDTK 47.09
  • AIM 39.82
  • Support Level
  • EDTK $0.97
  • AIM $0.11
  • Resistance Level
  • EDTK $1.03
  • AIM $0.16
  • Average True Range (ATR)
  • EDTK 0.03
  • AIM 0.02
  • MACD
  • EDTK -0.00
  • AIM 0.00
  • Stochastic Oscillator
  • EDTK 50.00
  • AIM 30.00

About EDTK Skillful Craftsman Education Technology Limited

Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Share on Social Networks: